No Data
No Data
Xinjiang Bai Hua Cun Pharma Tech (600721.SH) plans to participate in the Chongqing-Yuzhong Gaozhu New District Guangyi Xing (Chongqing) Private Equity Investment Fund.
Xinjiang Bai Hua Cun Pharma Tech (600721.SH) announced that its wholly-owned subsidiary, Nanjing Bai Hua Xin Biomedical Technology Co., Ltd., ...
Xinjiang Bai Hua Cun Pharma Tech (600721.SH): Subsidiary plans to participate in investment in pharmaceutical industry development fund.
On July 19, Gelunhui reported that Baihua Pharmaceutical (600721.SH) announced that its wholly-owned subsidiary Baihua Xin, Sichuan Yaoyigou Technology Group Co., Ltd., Guangan Investment Group Co., Ltd., and Beijing Hailianggaoke Technology Co., Ltd. served as limited partners, and Guangan Xiaopingguli Development Fund Management Co., Ltd. and Beijing Anlong Venture Capital Fund (Limited Partnership) served as general partners to jointly invest in the establishment of ChuanYu Gaozhu New District Guangyi Xing (Chongqing) Private Equity Investment Fund Partnership Enterprise (Limited Partnership). Baihua Xin uses its own funds to subscribe for 9.5 million yuan, accounting for 7.60% of the total subscribed capital of the target fund.
Announcement of the projected increase in performance for the first half of 2024 of the Xinjiang Baihua Village Pharmaceutical Group Co., Ltd.
Xinjiang Bai Hua Cun Pharma Tech (600721.SH) expects net income to increase by 35.38% to 103.08% in the first half of the year.
On July 10th, Gelunhui reported that Xinjiang Bai Hua Cun Pharma Tech (Stock Code: 600721.SH) expected to achieve a net income of 17.6 to 26.4 million yuan attributable to shareholders of listed companies in the first half of 2024, which is an increase of 4.6 to 13.4 million yuan compared to the same period last year, a year-on-year increase of 35.38% to 103.08%, based on the initial estimates of the company's financial department. The company is expected to achieve a net profit deducted from non-recurring gains and losses attributable to shareholders of listed companies of 16.5 to 24.5 million yuan in the first half of 2024, a year-on-year increase of 34.40% to 99.56% compared to the same period last year.
Xinjiang Bai Hua Cun Pharma Tech (600721.SH): Terminated the issuance of stocks and withdrew the application documents.
Xinjiang Bai Hua Cun Pharma Tech (600721.SH) issued an announcement that the company will hold the eighth board of directors meeting on June 28, 2024...
Shareholder Hua Ling Industry and Trade pledged 79,525,100 shares of Xinjiang Bai Hua Cun Pharma Tech (600721.SH).
Xinjiang Bai Hua Cun Pharma Tech (600721.SH) announced that its controlling shareholder, Hua Ling Gong Mao, has pledged 79,525,100 shares, accounting for 20.83% of the total share capital of the company.
No Data